Stocks Health care AGEN
NASDAQ · Health careAgenus Inc (AGEN)
Agenus Inc brought in $133.9M of revenue over the twelve months to September 30, 2026, up 25.4% from a year earlier. Net income was $29.5M, a net margin of 22.0%. In fiscal 2025 capital spending exceeded operating cash flow by $77.2M. At September 30, 2026 it held $66.9M in cash against $29.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Agenus Inc
- Net worth
- Agenus Inc has a market value (market cap) of $334.1M at the latest share price, and shareholders' equity of -$105.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $114.2M (+10.4% year on year), with a net loss of $101K. Over the 12 months to September 30, 2026: revenue $133.9M, net income $29.5M.
- Cash flow
- In fiscal 2025 operations used $77.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Agenus Inc's next report is expected around March 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Agenus Inc does
Agenus Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $114.2M | -$101K | $0.00 | -$77.2M |
| 2024 | $103.5M | -$227.4M | -$10.59 | -$158.9M |
| 2023 | $156.3M | -$246M | -$13.75 | -$234.2M |
| 2022 | $98M | -$220.3M | -$15.64 | -$228.4M |
| 2021 | $295.7M | -$24.1M | -$2.21 | -$23.7M |
| 2020 | $88.2M | -$181.1M | -$21.05 | -$142.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AGEN ranks in Health care
Latest SEC filings
What Agenus Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 4.1% to $31.5M versus the same quarter last year; diluted EPS $0.02 versus $1.94.
- November 5, 2026
- September 11, 2026
- September 2, 2026
- August 18, 2026
- August 13, 2026
- August 11, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 34% to $34.5M versus the same quarter last year; diluted EPS -$0.01 versus -$1.00.
- August 7, 2026
- August 7, 2026
Insider trades
What the people running Agenus Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Harrison Thomas LDirector | Received as pay | 4,443 | $30.6K |
| July 10, 2026 | Armen Garo HSee Remarks, Director | Received as pay | 4,852 | $16.3K |
| July 1, 2026 | Harrison Thomas LDirector | Received as pay | 8,547 | $30.6K |
| June 26, 2026 | Armen Garo HSee Remarks, Director | Received as pay | 5,364 | $16.3K |
| June 12, 2026 | Armen Garo HSee Remarks, Director | Received as pay | 4,925 | $16.3K |
| May 29, 2026 | Armen Garo HSee Remarks, Director | Received as pay | 4,644 | $16.3K |
| May 15, 2026 | Armen Garo HSee Remarks, Director | Received as pay | 4,540 | $16.3K |
| May 1, 2026 | Armen Garo HSee Remarks, Director | Received as pay | 4,233 | $16.3K |
Who owns AGEN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Raymond Debbane13G, passive with 7 related filers | 9.99% | July 17, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | July 20, 2026 |
| Zynext Ventures USA LLC13D, may seek influence with 2 related filers | 5.9% | January 23, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Greenwich Wealth Management LLC | 12,000 | 0 |
Insiders
2 insiders reported holding 423,096 shares in total, about $3.1M at the last price.
| Holder | Shares |
|---|---|
| Armen Garo HSee Remarks, Director | 371,108 |
| Harrison Thomas LDirector | 51,988 |
Questions about AGEN
What does Agenus Inc do?
Agenus Inc is a company in the Health care sector, listed on NASDAQ as AGEN. Its shares trade on NASDAQ under the ticker AGEN.
What is Agenus Inc's net worth?
Agenus Inc has a market value (market cap) of $334.1M at the latest share price, and shareholders' equity of -$105.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Agenus Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $29.5M on revenue of $133.9M, a net margin of 22.0%.
How much revenue does Agenus Inc make?
Over the twelve months to September 30, 2026 Agenus Inc reported revenue of $133.9M. That is 25.4% more than a year earlier.
When did Agenus Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Agenus Inc's next earnings report?
Agenus Inc's next report is expected around March 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AGEN with
Follow AGEN
Get an email when Agenus Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Agenus Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.